
Axcella Health AXLA
Quarterly report 2023-Q2
added 08-03-2023
Axcella Health Total Liabilities 2011-2026 | AXLA
Annual Total Liabilities Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.8 M | 35.7 M | 34.2 M | 34.1 M | 33.3 M | 165 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 165 M | 14.8 M | 52.9 M |
Quarterly Total Liabilities Axcella Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.5 M | 12 M | 14.8 M | 38.3 M | 40.7 M | 38.5 M | 35.7 M | 33.3 M | 33.4 M | 32.8 M | 34.2 M | 34.2 M | 34.2 M | 34.2 M | 34.1 M | 34.1 M | 34.1 M | 34.1 M | 33.8 M | 33.8 M | 33.8 M | 33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.7 M | 11.5 M | 31.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ADMA Biologics
ADMA
|
147 M | $ 16.54 | 0.98 % | $ 3.94 B | ||
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | ||
|
Apellis Pharmaceuticals
APLS
|
705 M | $ 19.86 | - | $ 2.51 B | ||
|
Aptorum Group Limited
APM
|
4.35 M | $ 0.83 | 4.19 % | $ 4.53 M | ||
|
AbCellera Biologics
ABCL
|
390 M | $ 3.63 | -2.16 % | $ 1.08 B | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
855 M | $ 76.53 | 0.57 % | $ 1.48 B | ||
|
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
602 M | $ 164.08 | 0.02 % | $ 8.16 B | ||
|
Champions Oncology
CSBR
|
28.6 M | $ 6.0 | - | $ 82 M | ||
|
BridgeBio Pharma
BBIO
|
3.01 B | $ 66.54 | 3.11 % | $ 12.7 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
9.6 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
1.45 B | $ 8.37 | - | $ 1.36 B | ||
|
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
25.4 M | $ 2.81 | - | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.51 B | $ 60.43 | 3.25 % | $ 11.6 B | ||
|
Cabaletta Bio
CABA
|
17.5 M | $ 3.43 | 5.54 % | $ 4.01 M | ||
|
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
387 M | $ 3.2 | 0.63 % | $ 1.15 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
36.1 M | $ 25.5 | -1.32 % | $ 683 M | ||
|
Agios Pharmaceuticals
AGIO
|
104 M | $ 28.19 | -1.02 % | $ 1.63 B | ||
|
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B |